Welcome to our dedicated page for Certara news (Ticker: CERT), a resource for investors and traders seeking the latest updates and insights on Certara stock.
Certara, Inc. reports developments in model-informed drug development, combining biosimulation software, technology and services for drug discovery, clinical development and regulatory science. Company news frequently centers on quarterly results, revenue mix between software and services, guidance updates and operating changes following the completed divestiture of its global medical writing and related regulatory services business.
Recurring updates also cover strategic partnerships with drug-development service providers and the use of Certara's Simcyp® Simulator for physiologically based pharmacokinetic modeling. These announcements describe biosimulation applications in clinical pharmacology, new drug applications and regulatory decision-making for biopharmaceutical, academic and agency clients.
Certara (Nasdaq: CERT) reported second quarter 2026 revenue from continuing operations of $93.3 million, up 1% year over year. Software revenue rose 4% to $48.8 million, while services revenue declined 3% to $44.5 million. Total bookings were $98.3 million, up 1%, with software bookings up 9% and services bookings down 6%.
The company posted a net loss from continuing operations of $6.1 million (diluted loss per share $(0.04)) versus net income of $1.5 million a year earlier. Adjusted EBITDA was $26.2 million, down 3%. Certara reaffirmed 2026 revenue guidance for continuing operations at 0%–4% growth ($367–$382 million), with expected adjusted EBITDA margin of 29%–31% and adjusted diluted EPS of $0.31–$0.36.
The company closed the divestiture of its Regulatory and Medical Writing business, executed a workforce reduction of about 5% targeting overhead, and expects run-rate savings of roughly $13 million. Certara completed a previously authorized $100 million share repurchase program, including $17.4 million in Q2, and the Board approved an additional $50 million authorization with no stated expiration.
Certara (Nasdaq: CERT) announced it will release its second quarter 2026 financial results before the market opens on Tuesday, August 4, 2026. Company management will hold a conference call at 8:30 AM ET, with live and archived webcast access via the Investors section of Certara’s website.
Certara (Nasdaq:CERT) announced a collaboration with NVIDIA to enhance its open integrated AI platform using the NVIDIA BioNeMo Agent Toolkit. The partnership connects Certara’s biosimulation software, proprietary datasets, and regulatory expertise with AI agents that can autonomously generate specialized insights across the drug discovery and development lifecycle.
These agents will reason over models and clinical data to optimize dosing, simulate trials, evaluate ADMET properties, and prepare regulatory-ready evidence, while keeping scientists in the decision-making loop.
Certara (Nasdaq:CERT) announced a Chief Financial Officer transition and reaffirmed its 2026 financial guidance. John Gallagher plans to resign as CFO at the end of July 14, 2026.
Faiz Mohammed, Senior Vice President of Finance and Treasurer, will serve as Interim CFO while a search is conducted.
Certara (Nasdaq:CERT) announced participation in several investor conferences. Management will present at the RBC CM Global Healthcare Conference on Tuesday, May 19 at 9:30 a.m. ET, William Blair’s 46th Annual Growth Stock Conference on Tuesday, June 2, and the Jefferies Global Healthcare Conference on Wednesday, June 3 at 1:20 p.m. ET.
Live webcasts for the RBC and Jefferies events, plus 90-day replays, will be available on Certara’s investor relations website.
Certara (Nasdaq:CERT) reported Q1 2026 revenue of $106.9 million, up 1% year over year. Software revenue rose 7% to $49.7 million, while services revenue fell 4% to $57.2 million.
The company posted a net loss of $8.8 million (‑$0.06 per share) versus prior-year net income of $4.7 million. Adjusted EBITDA was $31.7 million and adjusted net income was $14.5 million.
Certara completed the sale of its global medical and regulatory writing business to Veristat for $85 million cash, $15 million escrow, and up to $35 million in earn‑out. Updated 2026 guidance calls for revenue of $395–$405 million and adjusted EBITDA margin of 30%–32%.
Altasciences and Certara (Nasdaq: CERT) announced a strategic partnership on May 7, 2026 to integrate Certara's model-informed drug development (MIDD) and biosimulation into Altasciences' Acceleration Platform.
The collaboration aims to establish proof of mechanism earlier, optimize study designs and dosing, embed modeling into execution, and support faster go/no-go decisions across nonclinical, clinical, bioanalysis, and manufacturing workflows.
Certara (Nasdaq: CERT) agreed to sell its Regulatory and Medical Writing business to Veristat for up to $135 million, with closing expected in Q2 2026 subject to customary conditions.
In 2025 the unit generated $50 million revenue and $17 million adjusted EBITDA and includes ~220 employees. Certara will update 2026 guidance upon close and intends to deploy proceeds to advance its MIDD and Clinical Intelligence strategy.
Certara (Nasdaq: CERT) will report first quarter 2026 financial results before market open on Monday, May 11, 2026. Management will host a conference call at 8:30 AM ET to discuss results; registration is required and early registration is recommended. A live and archived webcast will be available in the Investors section of the Certara website.
Certara (Nasdaq: CERT) said its Simcyp Simulator PBPK modeling was accepted by the U.S. FDA in lieu of clinical studies to support the NDA for asciminib (Scemblix) for chronic myeloid leukemia. The modeling reportedly replaced at least ten dedicated clinical pharmacology studies and characterized asciminib pharmacokinetics across healthy volunteers and cancer patients.
The simulations bridged tested and untested scenarios, assessed drug–drug interactions, and supported dosing-regimen evaluation, reflecting a decade-long modeling effort and regulatory acceptance that reduced clinical study needs and development time.